Cholesterol-Lowering Therapy with Nexletol, Fenofibrate, and Ezetimibe

Introduction to Cholesterol-Lowering Agents

The American College of Cardiology recommends bempedoic acid as an optimal choice for statin-intolerant patients due to its meaningful LDL-C reduction (15-25%) without causing muscle-related side effects, and its proven cardiovascular outcomes benefit 1, 2, 3
Bempedoic acid has a muscle-sparing mechanism, activated only in the liver, eliminating statin-associated muscle symptoms, as supported by the American College of Cardiology 1, 2, 3, 4

The American College of Cardiology states that bempedoic acid has proven cardiovascular benefit, with the CLEAR Outcomes trial demonstrating a 13% reduction in major adverse cardiovascular events in statin-intolerant patients with established ASCVD or high risk 5, 6
Bempedoic acid effectively lowers LDL-C by approximately 24.5% as monotherapy in statin-intolerant patients, and 15-17.8% when added to statin therapy, according to the American College of Cardiology 1, 2, 3
The combination of bempedoic acid and ezetimibe achieves 38% LDL-C reduction, providing robust lipid control, as recommended by the American College of Cardiology 1, 2

The American College of Cardiology recommends ezetimibe as the first-line nonstatin therapy for all patients requiring additional LDL-C lowering, providing consistent 15-20% LDL-C reduction with minimal side effects 8, 6
Ezetimibe has an excellent safety profile, with minimal adverse effects, and is well-tolerated across all patient populations, including those with statin intolerance, as stated by the American College of Cardiology 8

The American College of Cardiology indicates that fenofibrate is specifically used for severe hypertriglyceridemia (>500 mg/dL) to prevent acute pancreatitis, and for mixed dyslipidemia when triglycerides and low HDL-C are the primary abnormalities, as supported by the American College of Cardiology 6
Fenofibrate reduces triglycerides by 40-57%, making it essential for pancreatitis prevention in severe hypertriglyceridemia, according to the American College of Cardiology 6

The American College of Cardiology recommends initiating ezetimibe 10 mg daily first, then adding bempedoic acid 180 mg daily if LDL-C targets are not met, reserving PCSK9 inhibitors for very high-risk patients with persistent elevation 8, 6
For very high-risk patients, the American College of Cardiology suggests adding bempedoic acid if LDL-C remains ≥55 mg/dL, and for high-risk patients, adding bempedoic acid if LDL-C remains ≥70 mg/dL 8, 6

The American College of Cardiology advises avoiding bempedoic acid in patients with a history of tendon rupture or active gout, and monitoring liver enzymes at baseline and periodically with all three agents 1, 2, 3, 8
The American College of Cardiology recommends considering cost, with ezetimibe being generic and affordable, bempedoic acid requiring prior authorization but having patient assistance programs, and PCSK9 inhibitors being the most expensive 1, 8